Autologous cryopreserved EBV specific cytotoxic T-cells therapy (University College London)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameAutologous cryopreserved EBV specific cytotoxic T-cells therapy (University College London)
Drug Alias NameCNA12 gene encoding retroviral vector (University College London/bluebird)tacrolimus-resistant autologous EBV-CTL cells (University College London/bluebird)tacrolimus-resistant autologous EBV-CTL cells (UCL/bluebird)ATIMP
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsLymphoproliferative Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesGenetix Biotherapeutics IncUniversity College London
Inactive CompaniesN/A
Active IndicationsLymphoproliferative Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A